



# Australia and New Zealand Fragility Fracture Registry (ANZFFR) Data Dictionary 2024

## Background

The Minimum Data Set (MDS) has been developed for the ANZ Fragility Fracture Registry Steering Committee. The MDS will capture information relevant to New Zealand and International Standards for Fracture Liaison Services. The purpose of the MDS and ANZ Fragility Fracture Registry (ANZFFR) is to support consistent, local collection of data across Australia and New Zealand to enable facilities to compare practice and outcomes for fragility fracture care against national clinical guidelines and standards of care. It is comparable to the United Kingdom (UK) national fracture liaison service database and other registries emerging across the world.

## Purpose

The goal of the ANZ Fragility Fracture Registry is to use data to drive excellence in the provision and equity of care of fragility fracture patients by Fracture Liaison Services (FLS) measured against the Clinical Standards for Fracture Liaison Services in Australia and New Zealand.

The Registry will enable:

- Monitoring of FLS performance over time against the Clinical Standards for Fracture Liaison Services in Australia and New Zealand. This will drive effective service delivery improvement by FLS and ensure that patients throughout Australia and New Zealand receive the optimal standards of care following a fragility fracture and to reduce the incidence of future fracture, especially hip fractures.
- Identification of unwarranted clinical variation in FLS service delivery and patient care across healthcare systems and allow respective FLS services to use the data to drive system level improvement.
- Provision of publicly available information so that patients can be reassured they receive the standard of care they need after a fragility fracture.
- Improvement in patient focus as over time we aim to have automatic uploading of patient data and direct reporting to reduce FLS administrative time.
- Provide data for research questions or projects, nationally and internationally, as required.

## MDS development

The MDS has been reviewed by the ANZ Fracture Registry Steering Committee, which consists of representatives of key professional and consumer bodies from Australia and New Zealand. This version of the ANZFFR Data Dictionary includes data variables for both the Patient Level Audit (the Registry) and the Facility Level Audit (annual snapshot of site level processes and protocols).

The data variables collected in the MDS (Patient Level) are from six (6) key components of care and include: (1) Patient information; (2) Fracture identification; (3) Assessment of bone health including DXA; (4) Falls screening assessment and referrals; (5) Treatment initiatives and referrals; and (6) Follow up information at 16 weeks and 52 weeks after index fracture.

The data variables collected in the MDS (Facility Level) cover: (1) Site Information; (2) Personnel; (3) Procedures; (4) Resources; and (5) Development.

## Review

The MDS will be reviewed annually by the ANZFFR Steering Committee. It is anticipated that any new item to be added must be presented with a clear case for the benefits of adding it. Equally the Committee will be charged with removing redundant items which are felt not to add value either at a facility or central level.

## Patient Inclusion

A person aged 50 years or older, who has been identified by a participating site with a fragility fracture which is defined as a fracture sustained after an impact equivalent to a fall from a standing height or lesser impact.

## Fracture Site Inclusion and Exclusion

Excluded fracture mechanisms:

- Periprosthetic fractures
- Fractures due to metastatic cancer or other intrinsic bone pathology
- High trauma fractures

Excluded fracture sites.

- Skull, facial bones, and jaw
- Cervical spine
- Carpals, metacarpals, and fingers
- Tarsals, metatarsals, and toes

Included fracture sites.

- All other sites as listed in data dictionary.

## Follow Up

Only patients who have been recommended to have osteoporosis specific treatment will be followed at 16 weeks and at 52 weeks after the index fragility fracture.

## Repeat Fractures

Repeat fractures (both before and after 52 weeks have elapsed since the index fracture) will initiate an additional episode of fracture care in the registry for that patient. A patient may therefore have several episodes of fracture care.

## Design

The MDS has been designed so that FLS staff can collect data and manage patients by telephone. This does not preclude managing patients in a face-to-face manner such as in a clinic environment or by written correspondence.

## List of Data Variables ANZFFR Patient Level Audit

### I. Patient Information

- I.01 FFR Identifier
- I.02 Facility ID
- I.03 Patient first name
- I.04 Patient last name
- I.05 Medicare Number / NHI
- I.06 Sex
- I.07 Date of birth
- I.08 Contact phone number
- I.09 Patient email
- I.10 Patient's post code
- I.11 New Zealand ethnic status
- I.12 Australian Indigenous status
- I.13 Age derived.
- I.14 Australian hospital medical record number

### 2. Identification

- 2.01 Index Fracture date
- 2.02 Primary index fracture site
- 2.03 Second index fracture site
- 2.04 Third index fracture site
- 2.05 Appropriate for further assessment
- 2.06 Reason not appropriate for further assessment.
- 2.07 Date Not Appropriate for Further Assessment
- 2.08 Type of fracture
- 2.09 Admission to hospital
- 2.10 Method of identification
- 2.11 Pre-fracture residence
- 2.12 Pre-fracture mobility
- 2.13 Pre-fracture cognitive status

### 3. Investigation - Bone Health Assessment

- 3.01 Date of assessment
- 3.02 Reported previous fragility fractures.
- 3.03 Parental history of hip fracture
- 3.04 Early menopause
- 3.05 Current smoker
- 3.06 Glucocorticoids
- 3.07 Rheumatoid arthritis
- 3.08 Alcohol use
- 3.09 Current osteoporosis specific treatment
- 3.10 Previous significant osteoporosis specific treatment
- 3.11 Thoraco-lumbar imaging
- 3.12 Thoraco-lumbar imaging date
- 3.13 Secondary cause review
- 3.14 Secondary cause blood tests
- 3.15 Creatinine clearance (Cockcroft Gault)
- 3.16 Patient weight
- 3.17 Patient height
- 3.18 Body mass index
- 3.19 FRAX score
- 3.20 Garvan score

### 4. Investigation - Falls Risk Assessment and Referrals

- 4.01 Falls risk assessment date
- 4.02 What happened.
- 4.03 Potential cardiac cause
- 4.04 Two or more slips, trips, and falls in previous 12 months.
- 4.05 Fear of falling
- 4.06 Pre-fracture strength
- 4.07 Strength and balance referrals
- 4.08 Strength and balance referral date
- 4.09 Information about Nymbi Provided
- 4.10 Referral for Specialist Falls Intervention.

## 5. Investigation - DXA

- 5.01 DXA ordered or not.
- 5.02 Date DXA ordered.
- 5.03 DXA date
- 5.04 DXA spine T-score
- 5.05 DXA hip T-score

## 6. Intervention

- 6.01 Osteoporosis specific treatment recommendation
- 6.02 Reason treatment not recommended.
- 6.03 Date of osteoporosis treatment recommendation
- 6.04 Vitamin D (Residential Aged Care Facility, RACF)
- 6.05 Long term plan
- 6.06 Long term plan date
- 6.07 Information package
- 6.08 Standard Information Package Date

## 7. Follow up at 16 weeks

- 7.01 Follow up at 16 weeks.
- 7.02 16-week follow up date.
- 7.03 16-week residence
- 7.04 16-week mobility
- 7.05 Medication commenced.
- 7.06 16-week medication
- 7.07 Strength and balance started.

## 8. Follow up at 52 weeks (50-54 weeks)

- 8.01 Follow up at 52 weeks.
- 8.02 52-week follow up date.
- 8.03 52-week residence
- 8.04 52-week mobility
- 8.05 52-week medication
- 8.06 Reason for no medication at 52 weeks
- 8.07 Further falls

8.08 Strength and balance

8.09 Further fracture

9. Additional Outcomes

9.01 Date of death

## List of Data Variables for ANZFFR Facility Level Audit

I. Facility Level Audit

6.01 FLS team meeting frequency

6.02 FLS external liaison meeting frequency

6.03 ANZFFR Annual Report Value 1

6.04 ANZFFR Annual Report Value 2

6.05 ANZFFR Annual Report Value 3

6.06 Database improvement feedback

6.07 Continuing professional development

## List of Data Variables ANZFFR Patient Level Audit

### I. Patient Information

<b>Variable #</b>	1.01	<b>Variable</b>	FFR identifier
<b>Variable Name</b>	FFRID	<b>Format</b>	Numeric
<b>Definition</b>	A consecutive number allocated to each patient record.		
<b>Justification</b>	To allow for the identification of unique records		
<b>Comments</b>	Required (system generated). This is the unique record number used to identify each record		

<b>Variable #</b>	1.02	<b>Variable</b>	Facility ID
<b>Variable Name</b>	facilityid	<b>Format</b>	Numeric
<b>Definition</b>	The system generated ID for the facility.		
<b>Justification</b>	To be able to allocate patient records to a facility.		
<b>Comments</b>	Required (system generated based on login)		

<b>Variable #</b>	1.03	<b>Variable</b>	Patient First Name
<b>Variable Name</b>	firstname	<b>Format</b>	String
<b>Definition</b>	First name of the patient		
<b>Justification</b>	To allow for checking of duplicate entries for the one person and to contact the patient for the follow-up.		
<b>Comments</b>	The format should be the same as that indicated by the person (for example written on a form) or in the same format as that printed on an identification card, such as Medicare card, or driver's license to ensure consistent collection of name data		



<b>Variable #</b>	1.04	<b>Variable</b>	Patient Last Name
<b>Variable Name</b>	lastname	<b>Format</b>	String
<b>Definition</b>	Last name of the patient		
<b>Justification</b>	To allow for checking of duplicate entries for the one person and to contact the patient for the follow-up.		
<b>Comments</b>	The format should be the same as that indicated by the person (for example written on a form) or in the same format as that printed on an identification card, such as Medicare card or driver's license, to ensure consistent collection of name data		

<b>Variable #</b>	1.05	<b>Variable</b>	Medicare Number / NHI
<b>Variable Name</b>	medicare	<b>Format</b>	String
<b>Definition</b>	Patient's Medicare or NHI number		
<b>Justification</b>	To allow for checking of duplicate entries for the one person and for multiple admissions		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand, required to save a record.</b></p> <p>Australia: Enter the full Medicare number for an individual (i.e., family number plus person individual reference number).</p> <p>New Zealand: Enter the National Health Index (NHI) which is a unique number assigned to every person who uses health and disability services in New Zealand. This is 3 letters followed by 4 numbers. The software uses an algorithm to check for illogical entries.</p>		

<b>Variable #</b>	1.06	<b>Variable</b>	Sex
<b>Variable Name</b>	sex	<b>Format</b>	Numeric
<b>Definition</b>	Sex of patient		
<b>Justification</b>	Basic demographic detail		
<b>Coding Source</b>	National Health Data Dictionary, Version 15		
<b>Coding Frame</b>	1 Male 2 Female 3 Intersex or indeterminate 4 Not stated / inadequately described		
<b>Comments</b>	Other includes Intersex or indeterminate, not stated or inadequately described		

<b>Variable #</b>	1.07	<b>Variable</b>	Date of Birth
<b>Variable Name</b>	dob	<b>Format</b>	Date
<b>Definition</b>	Date of birth of the patient		
<b>Justification</b>	Basic demographic details. Required for probabilistic data linkage in Australia.		
<b>Coding Source</b>	National Health Data Dictionary, Version 15 (METeOR identifier 287007)		
<b>Coding Frame</b>	dd/mm/yyyy		
<b>Comments</b>	Only include people who are 50 years or older at the time of their fracture.		



<b>Variable #</b>	1.08	<b>Variable</b>	Contact Phone Number
<b>Variable Name</b>	phone	<b>Format</b>	String
<b>Definition</b>	Contact phone number of the patient (including area code) or significant other (e.g., Enduring Power of Attorney, or family member),		
<b>Justification</b>	To contact the patient for follow up		
<b>Coding Source</b>			
<b>Coding Frame</b>	----- (? Number of spaces needed?) 00000000 = No phone number		
<b>Comments</b>			

<b>Variable #</b>	1.09	<b>Variable</b>	Patient Email
<b>Variable Name</b>	email	<b>Format</b>	String
<b>Definition</b>	Email of patient or significant other (e.g., Enduring Power of Attorney, or family member).		
<b>Justification</b>	To contact the patient for follow up and to send letters and other information.		
<b>Coding Source</b>			
<b>Coding Frame</b>	----- 0000 = not available		
<b>Comments</b>			

<b>Variable #</b>	I.10	<b>Variable</b>	Patient's Post Code
<b>Variable Name</b>	APcode	<b>Format</b>	String
<b>Definition</b>	What was the postcode of the suburb of the usual residence of the patient?		
<b>Justification</b>	Basic demographic details		
<b>Coding Source</b>	Australia Post or New Zealand Post websites ( <a href="http://www.auspost.com.au">www.auspost.com.au</a> or <a href="http://www.nzpost.co.nz">www.nzpost.co.nz</a> ) provide up-to-date postcodes and localities		
<b>Coding Frame</b>	1000 No fixed abode 9998 Overseas 9999 Postcode not known.		
<b>Comments</b>	Use a valid Australian or New Zealand postcode		

<b>Variable #</b>	1.11	<b>Variable</b>	New Zealand Ethnic Status
<b>Variable Name</b>	nzethnic	<b>Format</b>	Numeric
<b>Definition</b>	The ethnic group which the patient self identifies as belonging to.		
<b>Justification</b>	Basic demographic details		
<b>Coding Source</b>	Statistics New Zealand 2018 Census ethnicity question HISO 10001:2017 Ethnicity Data Protocols.		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. New Zealand European</li> <li>2. Māori</li> <li>3. Samoan</li> <li>4. Cook Island Māori</li> <li>5. Tongan</li> <li>6. Niuean</li> <li>7. Chinese</li> <li>8. Indian</li> <li>9. Not elsewhere included</li> <li>10. Other such as Dutch, Japanese, Tokelauan</li> </ol> <p>– 3 TEXT BOXES OF 12 SPACES</p> <p>All ethnicities are recorded as defined in 10001:2017 Ethnicity Data Protocols, and in</p> <p><a href="http://aria.stats.govt.nz/aria/#ClassificationView:uri=http://stats.govt.nz/cms/ClassificationVersion/YVqOcFHSIguKkTI7">http://aria.stats.govt.nz/aria/#ClassificationView:uri=http://stats.govt.nz/cms/ClassificationVersion/YVqOcFHSIguKkTI7</a></p>		

**Comments****S**

New Zealand only.

When completing this data item by interview, identify a standard place in the interview where the ethnicity question is to be asked. This place is most likely to be at the beginning or end of the interview, when other demographic information such as name, address, gender and age is collected.

At the start of the conversation, you should explain why you are phoning/collecting this data.

When asking the ethnicity question, the interviewer should state: "I am going to read out a list of ethnic groups. Can you tell me which ethnic group or groups you belong to?"

The interviewer should read out each of the categories and wait for a yes/no answer to each. When an answer is given, the interviewer continues asking the rest of the list until it is completed.

Asking the question in this way allows for more than one ethnicity to be selected. It also allows reporting of all other ethnic groups chosen by the person in the 'Another ethnic group' category.

It facilitates self-identification and allows the person to pick one or a number of categories that they identify with. This method reduces interviewer bias.

The final step is to confirm their ethnicity data. This means reading out all recorded variables, stating that this is the ethnicity information recorded currently for a respondent, and asking the respondent to confirm their ethnicity data.

Statistics NZ has an algorithm that is used to determine primary ethnic status. The double identification is handled by inviting individuals to record up to 3 ethnicities that they identify with. The algorithm is then used to identify a primary ethnicity.

<b>Variable #</b>	1.12	<b>Variable</b>	Australian Indigenous Status
<b>Variable Name</b>	ausindig	<b>Format</b>	Numeric
<b>Definition</b>	Is the patient of Aboriginal or Torres Straits Islander origin?		
<b>Justification</b>	Basic demographic details		
<b>Coding Source</b>	National Health Data Dictionary, Version 15 (METeOR identifier 291036)		
<b>Coding Frame</b>	1 Aboriginal but not Torres Strait Islander origin 2 Torres Strait Islander but not Aboriginal origin 3 Both Aboriginal and Torres Strait Islander origin 4 Neither Aboriginal nor Torres Strait Islander origin 9 Not stated / inadequately described		
<b>Comments</b>	An Aboriginal or Torres Strait Islander is a person of Aboriginal or Torres Strait Islander descent who identifies as an Aboriginal or Torres Strait Islander and is accepted as such by the community in which he or she lives. Collected Australia only		

<b>Variable #</b>	1.13	<b>Variable</b>	Age derived
<b>Variable Name</b>	Agederiv	<b>Format</b>	Numeric
<b>Definition</b>	Age of the patient in (completed) years at time of index fracture		
<b>Justification</b>	Basic demographic details		
<b>Coding Source</b>	National Health Data Dictionary, Version 15 (METeOR identifier 291036)		
<b>Coding Frame</b>	3 digits for age 999 Unknown / Not stated		
<b>Comments</b>	This variable can be used when providing de-identified data instead of potentially identifiable date of birth. It is calculated automatically from date of birth and date of index fracture. If age (or date of birth) is unknown and cannot be estimated Code 999.		

<b>Variable #</b>	I.14	<b>Variable</b>	Australian Hospital MRN / URN
<b>Variable Name</b>	AusMRN	<b>Format</b>	String (14)
<b>Definition</b>	Australian hospital medical record number		
<b>Justification</b>	Unique person-identifier for each patient in each hospital and contributes to collection of information on follow up e.g., re-operation		
<b>Coding Source</b>			
<b>Coding Frame</b>			
<b>Comments</b>	<p>Key field: must be entered to create a patient record.</p> <p>Individual hospitals use their own alphabetic, numeric, or alphanumeric coding systems.</p> <p>With the eventual move to E-Health in Australia, each patient will have a unique id nation-wide.</p> <p>Note: Western Australia uses URN.</p> <p>This variable will not be used in New Zealand.</p>		



## 2. Identification

<b>Variable #</b>	2.01	<b>Variable</b>	Index Fracture Date
<b>Variable Name</b>	fracturedate	<b>Format</b>	Date
<b>Definition</b>	Date the index fracture was diagnosed on medical imaging		
<b>Justification</b>	To enable time calculations for service levels and assessing Clinical Care Standards		
<b>Coding Source</b>	Radiology report		
<b>Coding Frame</b>	dd/mm/yyyy		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand, and to save record.</b></p> <p>The date of the medical imaging that confirmed the diagnosis is preferred because it is an objective measure.</p>		

<b>Variable #</b>	2.02	<b>Variable</b>	Primary Index Fracture Site
<b>Variable Name</b>	Fracturesitel	<b>Format</b>	Numeric
<b>Definition</b>	Where was the index fracture?		
<b>Justification</b>	Ability to assess patient outcome by type of fracture and to monitor the frequency of the various fracture types.		
<b>Coding Source</b>	Adapted from FLS Coding Guide, March 2020, National Osteoporosis Foundation		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Wrist</li> <li>2. Proximal humerus.</li> <li>3. Hip</li> <li>4. Thoraco-lumbar spine</li> <li>5. Sacrum and pelvis</li> <li>6. Other humerus</li> <li>7. Elbow</li> <li>8. Forearm other than wrist.</li> <li>9. Sternum, ribs, clavicle, and scapula</li> <li>10. Other femur including supracondylar knee.</li> <li>11. Tibial Plateau and patella</li> <li>12. Other lower leg and ankle</li> </ol>		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>There are 3 fracture site options to enable the recording of multiple fractures. The order of the entries should be prioritised Hip before Spinal before Non-hip / non-spine</p>		

<b>Variable #</b>	2.03	<b>Variable</b>	Second Index Fracture Site
<b>Variable Name</b>	Fracturesite2	<b>Format</b>	Numeric
<b>Definition</b>	Where was the second fracture?		
<b>Justification</b>	Ability to assess patient outcome by type of fracture and to monitor the frequency of the various fracture types.		
<b>Coding Source</b>	Adapted from FLS Coding Guide, March 2020, National Osteoporosis Foundation		
<b>Coding Frame</b>	<p>99. No second index fracture</p> <ol style="list-style-type: none"> <li>1. Wrist</li> <li>2. Proximal humerus.</li> <li>3. Hip</li> <li>4. Thoraco-lumbar spine</li> <li>5. Sacrum and pelvis</li> <li>6. Other humerus</li> <li>7. Elbow</li> <li>8. Forearm other than wrist.</li> <li>9. Sternum, ribs, clavicle, and scapula</li> <li>10. Other femur including supracondylar knee.</li> <li>11. Tibial Plateau and patella</li> <li>12. Other lower leg and ankle</li> </ol>		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>There are 3 fracture site options to enable the recording of multiple fractures that occurred at the time of the index fracture. The order of the entries should be prioritised Hip before Spinal before Non-hip / non-spine</p>		

<b>Variable #</b>	2.04	<b>Variable</b>	Third Index Fracture Site
<b>Variable Name</b>	Fracturesite3	<b>Format</b>	Numeric
<b>Definition</b>	Where was the primary fracture?		
<b>Justification</b>	Ability to assess patient outcome by type of fracture and to monitor the frequency of the various fracture types.		
<b>Coding Source</b>	Adapted from FLS Coding Guide, March 2020, National Osteoporosis Foundation		
<b>Coding Frame</b>	99. No third index fracture  1. Wrist 2. Proximal humerus. 3. Hip 4. Thoraco-lumbar spine 5. Sacrum and pelvis 6. Other humerus 7. Elbow 8. Forearm other than wrist. 9. Sternum, ribs, clavicle, and scapula 10. Other femur including supracondylar knee. 11. Tibial Plateau and patella 12. Other lower leg and ankle		
<b>Comments</b>	<b>Required for Clinical Standards for FLS in New Zealand</b>  There are 3 fracture site options to enable the recording of multiple fractures that occurred at the time of the index fracture. The order of the entries should be prioritised Hip before Spinal before Non-hip / non-spine.		

<b>Variable #</b>	2.05	<b>Variable</b>	Appropriate for Further Assessment
<b>Variable Name</b>	apprassess	<b>Format</b>	Numeric
<b>Definition</b>	Has a clinical decision been made that the clinical context of this patient means that any treatment for falls, or fracture prevention <b>IS</b> appropriate?		
<b>Justification</b>	To understand whether the nature of the clinical context of the patient means that any treatment is not appropriate and so further assessment is also not appropriate.		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Yes</li> <li>2. No</li> </ol>		
<b>Comments</b>	<p>There are likely to be a small proportion of patients for whom any treatment for falls or fracture prevention will be inappropriate given the nature of the clinical context. This would also mean that further assessment is also inappropriate.</p> <p>Examples include terminal illness / palliative care; end stage renal failure on renal replacement therapy; advanced malignancy with fragility fracture not due to metastasis.</p> <p>Answering <b>NO</b> will complete the ANZFFR entry after answering the next question and attributing a date to this decision.</p>		

<b>Variable #</b>	2.06	<b>Variable</b>	Reason Not Appropriate for Further Assessment
<b>Variable Name</b>	reasnotappr	<b>Format</b>	Numeric
<b>Definition</b>	What is the reason that a clinical decision has been made that the clinical context of this patient means that any treatment for falls, or fracture prevention is not appropriate?		
<b>Justification</b>	To understand the reason that the clinical decision has been made that any further assessment is not appropriate, because treatment would not be appropriate.		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Deceased</li> <li>2. Terminal illness / palliative care</li> <li>3. Frailty, life expectancy of less than a year / Advanced dementia</li> <li>4. End stage renal failure</li> <li>5. Advanced malignancy, # not due to metastasis.</li> <li>6. Usual residence not in New Zealand or Australia</li> <li>7. Other</li> <li>8. Under care of other specialist service</li> </ol>		
<b>Comments</b>	This will complete the ANZFFR entry for this patient after attributing a date to this decision.		

<b>Variable #</b>	2.07	<b>Variable</b>	Date Not Appropriate for Further Assessment
<b>Variable Name</b>	datenotappr	<b>Format</b>	Date
<b>Definition</b>	What is the date that a clinical decision has been made that the clinical context of this patient means that any treatment for falls, or fracture prevention is not appropriate?		
<b>Justification</b>	To know the date that this decision was made to enable comparison with the Clinical Standards for FLS in New Zealand.		
<b>Coding Source</b>			
<b>Coding Frame</b>	DD/MM/YY		
<b>Comments</b>	<b>Required for Clinical Standards for FLS in New Zealand</b>		

<b>Variable #</b>	2.08	<b>Variable</b>	Index Type of Fracture
<b>Variable Name</b>	fractype	<b>Format</b>	Numeric
<b>Definition</b>	Is the index fracture a primary fragility fracture or is it an atypical subtrochanteric femur fracture?		
<b>Justification</b>	To distinguish between a primary fragility fracture and a fracture secondary to bisphosphonate medication.  Optional		
<b>Coding Source</b>	Adapted from UK FLS Registry Data Definitions V2.0		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Fragility</li> <li>2. Atypical</li> </ol>		
<b>Comments</b>	<ul style="list-style-type: none"> <li>● Atypical refers to the subtrochanteric femoral fracture that is recognised to be bisphosphonate related.</li> <li>● According to the ASBMR 2013 Taskforce, an atypical femur fracture (AFF) must be located along the femoral diaphysis from just distal to the lesser trochanter to just distal to the supracondylar flare. In addition, 4 of 5 major features must be present.</li> <li>● Major features of AFF: fracture is associated with minimal or no trauma; the fracture line originates at the lateral cortex and is substantially transverse in its orientation, although it may become oblique as it progresses medial across the femur; complete fractures extend through both cortices and may be associated with a medial spike; the fracture is non-comminuted or minimally comminuted; Localized periosteal or endosteal thickening of the lateral cortex is present at the fracture site (“beaking” or “flaring”)</li> <li>● This diagnosis should be discussed with the Orthopaedic / other medical team to ensure appropriate radiological screening of contralateral femur has been done and reviewed.</li> <li>● The case should be discussed with the Clinical lead and appropriate follow up arranged.</li> </ul>		



<b>Variable #</b>	2.09	<b>Variable</b>	Admission to Hospital
<b>Variable Name</b>	hospadm	<b>Format</b>	Numeric
<b>Definition</b>	Has the person been admitted to an inpatient bed as a direct result of the index fragility fracture?		
<b>Justification</b>	To ascertain if the index fracture has resulted in an episode of inpatient care. This is an outcome measure and a proxy measure for resource consumption.  Optional		
<b>Coding Source</b>	Adapted from UK FLS Registry Data Definitions V2.0		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Yes</li> <li>2. No</li> <li>3. Already an inpatient</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	This includes both an admission to hospital at the time of the fracture and / or a later elective admission. Includes admissions to a medical assessment unit and day case surgery. In New Zealand an admission is defined as a stay in hospital of longer than six hours.		

<b>Variable #</b>	2.10	<b>Variable</b>	Method of Identification
<b>Variable Name</b>	idmethod	<b>Format</b>	Numeric
<b>Definition</b>	What was the first method used to identify that this person had a fragility fracture?		
<b>Justification</b>	To ascertain the method used by the Fracture Liaison Staff to identify the fragility fracture.  Optional		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Emergency Department trauma list</li> <li>2. Inpatient diagnosis list (filtered for fracture)</li> <li>3. Fracture clinic list</li> <li>4. Internal hospital referral</li> <li>5. GP referral</li> <li>6. ACC fracture claims</li> <li>7. Discharge coding</li> <li>8. Radiology reports for any fracture</li> <li>9. Radiology other</li> <li>10. Radiology reports for vertebral fractures (“wedge, compression etc”)</li> <li>11. Out of area referral</li> <li>12. External – FLS to FLS</li> </ol>		
<b>Comments</b>	<p>Record the first method by which the patient was identified.</p> <p>Collecting this information will help determine the most efficient method for identifying fragility fractures in order to meet the Key Performance Indicators (KPI’s) for the Clinical Standards for FLS in New Zealand.</p>		

<b>Variable #</b>	2.11	<b>Variable</b>	Pre-fracture Residence
<b>Variable Name</b>	fractureresidence	<b>Format</b>	Numeric
<b>Definition</b>	What is the usual place of residence of the patient prior to having the fragility fracture?		
<b>Justification</b>	This enables comparison of the type of accommodation of the person before suffering a fragility fracture with that at follow up assessments. This is an indicator of patient outcome.		
<b>Coding Source</b>	Adapted from the Australasian Rehabilitation Outcomes Centre Inpatient Dataset, Version 3.0; NSW SNAP Data Collection, Version 4.0		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Private residence (including unit in retirement village)</li> <li>2. Residential aged care facility</li> <li>3. Other</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	<ul style="list-style-type: none"> <li>● Record the patient's usual accommodation type at admission.</li> <li>● Residential aged care refers to a supported facility that provides accommodation and care for a person on a long-term basis. This may include multi-purpose services in Australia and private hospitals or rest homes in New Zealand.</li> <li>● If the patient lives with a relative or in a community group home or boarding house code 'private residence'.</li> <li>● If the patient was admitted from respite care, record their usual place of residence when not in respite care.</li> </ul>		

<b>Variable #</b>	2.12	<b>Variable</b>	Pre-fracture Mobility
<b>Variable Name</b>	walkpf	<b>Format</b>	Numeric
<b>Definition</b>	The patient's mobility status prior to the index fragility fracture		
<b>Justification</b>	To document the patient's pre-fracture mobility. This helps to assess the risk of falls and consequently the risk of further fragility fractures.		
<b>Coding Source</b>	Adapted from ANZHFR Data Dictionary V13		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Usually walks without walking aids.</li> <li>2. Usually walks with either a stick or crutch.</li> <li>3. Usually walks with two aids or frame (with or without assistance of a person)</li> <li>4. Usually uses a wheelchair / bed bound.</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	If a person has different levels of mobility on different surfaces, then record the level of most assistance. For example, inside their residence a person usually walks without a walking aid but when outside the residence the person usually walks with a frame, then the level of mobility recorded is option 3.		

<b>Variable #</b>	2.13	<b>Variable</b>	Pre-fracture Cognitive Status
<b>Variable Name</b>	cogstat	<b>Format</b>	Numeric
<b>Definition</b>	What was the cognitive status of the patient prior to the index fracture?		
<b>Justification</b>	To enable the identification of the cognitive status of the patient prior to the index fracture which is risk factor for future falls and fractures.		
<b>Coding Source</b>	Adapted from ANZHFR Data Dictionary V13		
<b>Coding Frame</b>	1 Normal cognition 2 Impaired cognition or known dementia. 9 Not known.		
<b>Comments</b>	<p>Normal cognition refers to ‘no history of cognitive impairment or dementia’.</p> <p>Impaired cognition or known dementia refers to a ‘loss of cognitive ability and/or a decline in memory or other thinking skills severe enough to reduce a person’s ability to perform everyday activities’ (Alzheimer’s Association).</p> <p>This information can be obtained from medical letters, inpatient notes, GP referrals or from information shared by family members.</p> <p>People with impaired cognition are at high risk of falls. Clinical judgement should be used to decide whether a referral to a Geriatrician or community Gerontology Nurse Specialist would be helpful.</p>		

### 3. Investigation - Bone Health Assessment

<b>Variable #</b>	3.01	<b>Variable</b>	Bone Health Assessment Date
<b>Variable Name</b>	dateassessb	<b>Format</b>	Date and Numeric
<b>Definition</b>	This is the date the patient was assessed for bone health and future fracture risk after sustaining the index fracture.		
<b>Justification</b>	To record details of the patient's bone health to assess the risk of future fragility fractures and to assess fracture management against Clinical Care Standards.		
<b>Coding Source</b>	Adapted from UK FLS-DB Proforma v2.0		
<b>Coding Frame</b>	__ / __ / _____ OR 1. Patient did not attend / declined = 11/11/1111 2. Patient died before assessment = 99/99/9999		
<b>Comments</b>	<b>Required for Clinical Standards for FLS in New Zealand</b> This is the date that the assessment took place. The assessment can be in person or by telephone interview. NZ Standard FLS Clinical Care Standard requires this to be completed within 12 weeks of index fracture.		

<b>Variable #</b>	3.02	<b>Variable</b>	Reported Previous Fragility Fractures
<b>Variable Name</b>	prevff	<b>Format</b>	Numeric
<b>Definition</b>	The number of fragility fractures the patient has suffered after 50 years of age, prior to the index fracture.		
<b>Justification</b>	To assess bone health and the risk of future fragility fractures		
<b>Coding Source</b>			
<b>Coding Frame</b>	0. 0 1. 1 2. 2 3. 3 or more 9. Not known		
<b>Comments</b>	This is the number of low impact fractures (equivalent to a fall from a standing height) that the patient has suffered since they turned 50 years old, and prior to the index fracture. Note: please note the fracture sites that are an exclusion for this registry.		

<b>Variable #</b>	3.03	<b>Variable</b>	Parental History of Hip Fracture
<b>Variable Name</b>	fhxhipfrax	<b>Format</b>	Numeric
<b>Definition</b>	Has either biological parent suffered a fragility fracture of the proximal femur / hip?		
<b>Justification</b>	To assess bone health and the risk of future fragility fractures.		
<b>Coding Source</b>	Adapted from the UK FLS DB V2.00 and FRAX		
<b>Coding Frame</b>	1. Yes 2. No 3. Not done		
<b>Comments</b>	Please select 'No' if the patient cannot answer this question, e.g., adopted or don't know. Take care not to enter family members having hip replacements for osteo-arthritis.		

<b>Variable #</b>	3.04	<b>Variable</b>	Early Menopause
<b>Variable Name</b>	earlymen	<b>Format</b>	Numeric
<b>Definition</b>	Female patient has experienced menopause before age 45 years		
<b>Justification</b>	To assess bone health and the risk of future fragility fractures.		
<b>Coding Source</b>	FRAX		
<b>Coding Frame</b>	1 Yes 2 No 3 Not done		
<b>Comments</b>	Note: need to have a skip function for males		

<b>Variable #</b>	3.05	<b>Variable</b>	Current Smoker
<b>Variable Name</b>	smoke	<b>Format</b>	Numeric
<b>Definition</b>	Has the patient inhaled any tobacco in the last week?		
<b>Justification</b>	To assess bone health and the risk of future fragility fractures.		
<b>Coding Source</b>	Adapted from the UK FLS DB V2.00		
<b>Coding Frame</b>	1 Yes 2 No 3 Not done.		
<b>Comments</b>	This risk factor appears to have a dose-dependent effect, i.e., the higher the exposure, the greater the risk. This is not taken into account and the computations assume average exposure. Clinical judgment should be used for low or high exposures.		



<b>Variable #</b>	3.06	<b>Variable</b>	Glucocorticoids
<b>Variable Name</b>	gcort	<b>Format</b>	Numeric
<b>Definition</b>	Has the patient had significant exposure to oral glucocorticoids?		
<b>Justification</b>	To assess bone health and the risk of future fragility fractures.		
<b>Coding Source</b>	Adapted from FRAX		
<b>Coding Frame</b>	1 Yes 2 No 3 Not done		
<b>Comments</b>	<p>Answer yes if the patient is currently taking oral glucocorticoids or has had has been exposed to oral glucocorticoids for more than 3 months at a dose of prednisolone of 5mg daily or more (or equivalent doses of other glucocorticoids)</p> <p>This risk factor appears to have a dose-dependent effect, i.e., the higher the exposure, the greater the risk. This is not taken into account and the computations assume average exposure. Clinical judgment should be used for low or high exposures.</p>		

<b>Variable #</b>	3.07	<b>Variable</b>	Rheumatoid Arthritis
<b>Variable Name</b>	rheumatoid	<b>Format</b>	Numeric
<b>Definition</b>	Does the patient have a confirmed diagnosis of rheumatoid arthritis?		
<b>Justification</b>	To assess bone health and the risk of future fragility fractures.		
<b>Coding Source</b>	Adapted from FRAX		
<b>Coding Frame</b>	1 Yes 2 No 3 Not done		
<b>Comments</b>	<p>Rheumatoid Arthritis is a risk factor for fracture. However, osteoarthritis is, if anything, protective. For this reason, reliance should not be placed on a patient's report of 'arthritis' unless there is clinical or laboratory evidence to support the diagnosis.</p>		

<b>Variable #</b>	3.08	<b>Variable</b>	Alcohol Use
<b>Variable Name</b>	Alcohol	<b>Format</b>	Numeric
<b>Definition</b>	Does the patient consume 3 or more standard drinks per day on average		
<b>Justification</b>	To assess bone health and the risk of future fragility fractures.		
<b>Coding Source</b>	FRAX		
<b>Coding Frame</b>	1 Yes 2 No 3 Not done		
<b>Comments</b>	<p>Enter yes if the patient takes 3 or more units of alcohol daily. A unit of alcohol varies slightly in different countries from 8-10g of alcohol. This is equivalent to a standard glass of beer (285ml), a single measure of spirits (30ml), a medium-sized glass of wine. (120ml), or 1 measure of an aperitif (60ml).</p> <p>This risk factor appears to have a dose-dependent effect, i.e., the higher the exposure, the greater the risk. This is not considered, and the computations assume average exposure. Clinical judgment should be used for low or high exposures.</p>		

<b>Variable #</b>	3.09	<b>Variable</b>	Current Osteoporosis Specific Treatment
<b>Variable Name</b>	currentoptreat	<b>Format</b>	Numeric
<b>Definition</b>	What osteoporosis specific treatment was prescribed at the time of the index fracture?		
<b>Justification</b>	Ability to monitor use of osteoporosis specific treatment at the time index fracture		
<b>Coding Source</b>	Adapted from the UK National Hip Fracture Database & ANZ Hip Fracture Registry and UK FLS-DB Proforma V2.00		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. No osteoporosis specific treatment at time of index fracture</li> <li>2. Not taking medication because of a planned “drug holiday”</li> <li>3. Alendronate</li> <li>4. Risedronate</li> <li>5. Etidronate</li> <li>6. Zoledronate</li> <li>7. Denosumab</li> <li>8. Teriparatide</li> <li>9. Testosterone</li> <li>10. Systemic Oestrogens</li> <li>11. Systemic Oestrogen &amp; Progesterone</li> <li>12. Romosozumab</li> <li>13. Raloxifene</li> <li>99. Not known</li> </ol>		

**Comments**

A patient is to be considered as 'on/taking' osteoporosis specific treatment if:

- For oral bisphosphonates, prescribed in the last 12 weeks.
- For Zoledronate, administered in the last 24 months.
- For Denosumab, administered the last 6 months.
- For Teriparatide, administered in the last 7 days.
- For Romosozumab, administered in the last month.

These medications may be prescribed with or without calcium and / or vitamin D.

If unsure as to the type of Hormone replacement therapy (HRT) please select Systemic Oestrogen & Progesterone.

In Australia, information will be only from patient interview. In NZ information is from a combination of patient interview and electronic linkage.

<b>Variable #</b>	3.10	<b>Variable</b>	Previous Significant Osteoporosis Specific Treatment
<b>Variable Name</b>	prevoptreat	<b>Format</b>	Numeric
<b>Definition</b>	Has the patient had significant osteoporosis specific treatment prior to this index fracture, but is not taking osteoporosis specific treatment at the time of the index fracture?		
<b>Justification</b>	Ability to monitor previous significant osteoporosis specific treatment.		
<b>Coding Source</b>	Adapted from the UK National Hip Fracture Database & ANZ Hip Fracture Registry and UK FLS-DB Proforma V2.00		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Yes</li> <li>2. No</li> <li>3. Not done</li> </ol>		
<b>Comments</b>	<p><b>Note:</b> Previous significant osteoporosis pharmacotherapy is one of the medications listed below for duration of at least one year.</p> <ul style="list-style-type: none"> <li>● oral bisphosphonates</li> <li>● Zoledronate infusion</li> <li>● Denosumab</li> <li>● Teriparatide</li> <li>● Romosozumab</li> <li>● Raloxifene</li> <li>● Systemic Oestrogens</li> <li>● Systemic Oestrogen &amp; Progesterone</li> <li>● Testosterone</li> </ul> <p>These medications may be prescribed with or without calcium and / or vitamin D.</p>		

<b>Variable #</b>	3.11	<b>Variable</b>	Thoraco-Lumbar Spine Imaging
<b>Variable Name</b>	timage	<b>Format</b>	Numeric
<b>Definition</b>	Has a vertebral fracture been identified on thoraco-lumbar spine imaging in the 5 years before the index fracture for this record?		
<b>Justification</b>	To assess the risk of future fragility fractures and the requirement for treatment.		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Fracture identified.</li> <li>2. No fracture identified.</li> <li>3. No imaging of thoraco-lumbar spine performed or report not available.</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	<p>Answer <i>“Fracture identified”</i> if the patient had a vertebral fracture identified on thoraco-lumbar imaging in the 5 years before the fracture leading to the creation of this database record.</p> <p>A vertebral fracture is defined by the Pharmaceutical Benefits Scheme in Australia, as a 20% or greater reduction in height of the anterior or mid-portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.</p> <p>The imaging may be in the form of a thoraco-lumbar spine x-ray, lateral chest x-ray, bone scan, CT scan, MRI or vertebral fracture assessment using a DXA scan.</p> <p>Answer <i>“No fracture identified”</i> if imaging has been done and there were no vertebral fractures identified.</p>		

<b>Variable #</b>	3.12	<b>Variable</b>	Thoraco-lumbar Imaging Date
<b>Variable Name</b>	tldate	<b>Format</b>	Date
<b>Definition</b>	If vertebral fracture identified, date of thoraco-lumbar imaging		
<b>Justification</b>	To ascertain the date that the thoraco-lumbar imaging was performed.		
<b>Coding Source</b>			
<b>Coding Frame</b>	dd/mm/yyyy 00/00/0000 = not done		
<b>Comments</b>	Note: If more than one, give the date of the most recent image showing a vertebral fracture <i>before</i> the current (index) fracture.		

<b>Variable #</b>	3.13	<b>Variable</b>	Secondary Cause Review
<b>Variable Name</b>	secondarycause	<b>Format</b>	Numeric
<b>Definition</b>	Have the past medical history, problem lists in clinical letters, other relevant clinical documents and recent blood tests been reviewed by the clinical team to identify and consult about possible secondary causes of osteoporosis due to disease and medication?		
<b>Justification</b>	To assess bone health and the risk of future fragility fractures.		
<b>Coding Source</b>			
<b>Coding Frame</b>	1. Yes 2. No 3. Not done		
<b>Comments</b>	Note that while it is important to identify secondary causes, most cases will still require osteoporosis pharmacotherapy. Treatment of the secondary cause may reduce risk of future fragility fracture.  See the separate information sheet.		

<b>Variable #</b>	3.14	<b>Variable</b>	Secondary Cause Blood Tests
<b>Variable Name</b>	secbloods	<b>Format</b>	Numeric (more than one possible choice)
<b>Definition</b>	A basic panel of blood tests (see list below) to check for secondary causes of osteoporosis and fragility fractures has been performed if indicated.		
<b>Justification</b>	To assess bone health and the risk of future fragility fractures.		
<b>Coding Source</b>	Guidance on Diagnosis and Management of Osteoporosis in New Zealand, 2017		
<b>Coding Frame</b>	<p>Position Statement on the Management of Osteoporosis, February 2021, Healthy Bones Australia.</p> <ol style="list-style-type: none"> <li>1. Yes – all normal</li> <li>2. No</li> <li>3. Not clinically indicated.</li> <li>4. Referred to another clinical team (including GP)</li> <li>5. Yes – at least one result reported as abnormal</li> </ol>		
<b>Comments</b>	<p><b>The recommended list of initial blood tests is:</b></p> <p>Renal function tests (creatinine and electrolytes), Liver function tests including alkaline phosphatase, Ca, PO4 and TSH.</p> <p>[25(OH) vitamin D is not available to GPs in New Zealand, so not included on this list]</p> <p>25(OH) vitamin D remains on the list for Australia.</p> <p><b>Further investigations as required include:</b></p> <p>PTH, ESR/CRP, 25(OH) vitamin D, serum protein electrophoresis / immunoelectrophoresis, serum free light chains/urine Bence Jones protein, Coeliac screen, hypercortisolism screen, 24-hour urine calcium and creatinine excretion. Testosterone (in males only), E2, LH and FSH in women if premature menopause is suspected.</p> <p><b>Note:</b> Blood test results from the previous 3 months are eligible provided the patient’s medical condition has been stable.</p> <p>All abnormal results require discussion with the Clinical Lead.</p>		



“Relevant blood and urine studies should be obtained prior to initiating therapy if the medical history and / or clinical examination is compatible with secondary osteoporosis, or the Z-score is  $\leq -2.0$  “

(Royal Australian College of General Practitioners: Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age, 2nd edition, 2017)

<b>Variable #</b>	3.15	<b>Variable</b>	Creatinine Clearance (Cockcroft Gault)
<b>Variable Name</b>	CrCl	<b>Format</b>	Numeric: ml/min
<b>Definition</b>	The estimated Creatinine Clearance using the Cockcroft Gault formula		
<b>Justification</b>	To assess bone health and the risk of future fragility fractures and to ensure safe use of bone protection medication as the dose may need to be adjusted based on renal function.		
<b>Coding Source</b>	Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. PubMed PMID: 1244564		
<b>Coding Frame</b>	_ _ _ ml/min. Not calculated = 000		
<b>Comments</b>	All formulae estimating creatinine clearance are just that – estimates. The Cockcroft Gault equation is widely used by pharmaceutical companies for estimating creatinine clearance. Inaccuracies arise due to variations in body composition among patients. The original formula used lean body weight. If the patient is overweight clinical judgement is required to adjust the value of the weight in the formula.		

<b>Variable #</b>	3.16	<b>Variable</b>	Patient Weight
<b>Variable Name</b>	pweight	<b>Format</b>	Numeric
<b>Definition</b>	Patient weight in kilograms at time of assessment		
<b>Justification</b>	To assess bone health and the risk of future fragility fractures		
<b>Coding Source</b>			
<b>Coding Frame</b>	Numeric ___ Kg Not done = 000		
<b>Comments</b>	While it may only be possible to ask the patient and record their answer in a telephone interview, objective information is preferred. Examples: recently recorded weight at General Practice; weight recorded while an inpatient or at an outpatient attendance.		

<b>Variable #</b>	3.17	<b>Variable</b>	Patient Height
<b>Variable Name</b>	pheight	<b>Format</b>	Numeric
<b>Definition</b>	Height of patient in metres		
<b>Justification</b>	To assess bone health and the risk of future fragility fractures		
<b>Coding Source</b>			
<b>Coding Frame</b>	___ cm Not done = 000		
<b>Comments</b>	While it may only be possible to ask the patient and record their answer in a telephone interview, objective information is preferred. Examples: recently recorded height at General Practice; height recorded while and inpatient or at an outpatient attendance or from DXA scan.		

<b>Variable #</b>	3.18	<b>Variable</b>	Body Mass Index
<b>Variable Name</b>	bmi	<b>Format</b>	Numeric
<b>Definition</b>	Body Mass Index derived from height and weight in Kg/m <sup>2</sup>		
<b>Justification</b>	To assess bone health and the risk of future fragility fractures		
<b>Coding Source</b>	Adophe Quetelet equation. Gadzik J “How much should I weight? Quetelet’s equation, upper weighth limits and BMI prime”. Connecticut Medicine (2006). 70 (2): 81-8. PMID 1676 8059.		
<b>Coding Frame</b>	<p>— . —</p> <p>[This will be automatically filled based on previous information?]</p> <p>Not calculated = 00.0</p>		
<b>Comments</b>	<p>Interpretation: &lt;18.5 Underweight; 18.5-24.9 Normal weight; 25.0-29.9 Overweight; &gt; 30.0 Obese. Note: low body weight is a risk factor for developing osteoporosis.</p>		

<b>Variable #</b>	3.19	<b>Variable</b>	FRAX Score
<b>Variable Name</b>	frax	<b>Format</b>	Numeric
<b>Definition</b>	The 10-year risk of hip fracture using the FRAX fracture risk calculator		
<b>Justification</b>	To assess the risk of future fragility fractures and hip fracture in particular		
<b>Coding source</b>	FRAX online fragility fracture risk assessment tool		
<b>Coding Frame</b>	__ % 00 not done. 99 not appropriate		
<b>Comments</b>	This is one factor to contribute to the decision about whether treatment is appropriate for this patient.  This assessment is not appropriate for patients aged 90 years and older.		

<b>Variable #</b>	3.20	<b>Variable</b>	Garvan Score
<b>Variable Name</b>	garvan	<b>Format</b>	Numeric
<b>Definition</b>	The 10-year risk of hip fracture using the Garvan fracture risk calculator		
<b>Justification</b>	To assess the risk of future fragility fractures and hip fracture in particular		
<b>Coding source</b>	Garvan online fragility fracture risk assessment tool		
<b>Coding Frame</b>	__ % 00 not done. 99 not appropriate		
<b>Comments</b>	This is one factor to contribute to the decision about whether treatment is appropriate for this patient.		

#### 4. Investigation - Falls Risk Assessment and Referrals

<b>Variable #</b>	4.01	<b>Variable</b>	Falls Risk Assessment Date
<b>Variable Name</b>	fallsassessdate	<b>Format</b>	date
<b>Definition</b>	The date that FLS compiled the data required in the Falls Screen		
<b>Justification</b>	To understand the risk factors for future falls and fractures		
<b>Coding Source</b>			
<b>Coding Frame</b>	dd/mm/yyyy 99/99/9999 not done.		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>The falls risk assessment is the collection of information either by patient interview or from other sources such as hospital inpatient or outpatient notes / letters or General Practitioner information.</p> <p>This information is compiled as part of the FLS assessment process.</p>		

<b>Variable #</b>	4.02	<b>Variable</b>	What Happened
<b>Variable Name</b>	whathap	<b>Format</b>	Free Text
<b>Definition</b>	Description of incident that led to the fracture		
<b>Justification</b>	To ensure that a history of the incident (fall, trip, slip) that led to the fracture is recorded and then used to inform appropriate further referrals.		
<b>Coding Source</b>			
<b>Coding Frame</b>	Text		
<b>Comments</b>	<p>Please clarify with the patient / informant that this fracture was a result of minimal level trauma (equivalent to a fall from a standing height).</p> <p>Please remember that the fall may be associated with acute illness, and this may be the main precipitating cause.</p> <p>After the patient has explained what happened, further questioning should attempt to elicit the underlying mechanism of the fall.</p> <ul style="list-style-type: none"> <li>● Is there a clear history of an external factor being involved in the trip / slip?</li> <li>● Did they lose their balance?</li> <li>● Were there prodromal symptoms?</li> <li>● Was the fall and / or the prodromal symptoms related to change in posture?</li> <li>● Do they remember hitting the ground or did they just wake up on the floor?</li> <li>● Could they get up unassisted after their fall?</li> </ul> <p>See separate document regarding falls risk assessment and referrals.</p>		

<b>Variable #</b>	4.03	<b>Variable</b>	Potential Cardiac Cause
<b>Variable Name</b>	Heartcause	<b>Format</b>	Numeric / multichoice
<b>Definition</b>	Were there any symptoms at the time of the fall, that may suggest a cardiac cause?		
<b>Justification</b>	To ascertain if there were symptoms that might suggest a cardiac cause of the fall and to inform appropriate further referrals.		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Can't remember landing on floor / woke up on floor.</li> <li>2. Loss of consciousness / fainted.</li> <li>3. Prodromal symptoms associated with postural change (dizziness, light headedness, nausea, diaphoresis, palpitations, chest pain)</li> <li>4. No symptoms</li> <li>5. Not assessed</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	<p>The aim of these questions is to help a decision about referrals for further evaluation. It is important to consider the clinical context of the person e.g., do they have significant cardiac history and are they are on medications that can possibly cause these symptoms.</p> <p>Suggested referrals if question answer is positive:</p> <ol style="list-style-type: none"> <li>1. Discussion with FLS Clinical Lead and consider referral to physician / geriatrician.</li> <li>2 and 3.</li> </ol> <p>Referral to GP or other medical person for review of medication and lying and standing BP and possibly an ECG.</p> <p>See separate document regarding falls risk assessment and referrals.</p>		

<b>Variable #</b>	4.04	<b>Variable</b>	Two or More Slips, Trips and Falls in Previous 12 months
<b>Variable Name</b>	falls12	<b>Format</b>	Numeric
<b>Definition</b>	Has the patient had two or more slips, trips, or falls in the 12 months prior to the index fracture?		
<b>Justification</b>	To assess the risk of falls and consequently the risk of further fragility fractures.		
<b>Coding Source</b>	<a href="https://www.hqsc.govt.nz/our-programmes/reducing-harm-from-falls/publications-and-resources/publication/1458/">https://www.hqsc.govt.nz/our-programmes/reducing-harm-from-falls/publications-and-resources/publication/1458/</a>		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Yes</li> <li>2. No</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	<p>Two or more slips, trips, or falls in the previous 12 months puts the patient at high risk of further falls and referral to a falls prevention service / strength and balance programme should be considered.</p> <p>There is evidence that even after one fall in the previous year a referral to a strength and balance programme may be appropriate, depending on the clinical situation.</p>		



<b>Variable #</b>	4.05	<b>Variable</b>	Fear of Falling
<b>Variable Name</b>	fallsfear	<b>Format</b>	Numeric
<b>Definition</b>	Does the patient have “fear of falling” or anxiety about falls?		
<b>Justification</b>	To assess the risk of falls and consequently the risk of further fragility fractures.		
<b>Coding Source</b>	<a href="https://www.hqsc.govt.nz/our-programmes/reducing-harm-from-falls/publications-and-resources/publication/1458/">https://www.hqsc.govt.nz/our-programmes/reducing-harm-from-falls/publications-and-resources/publication/1458/</a>		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Yes</li> <li>2. No</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	<p>Please ask the patient the following two questions - “Have you avoided some activities because you might lose your balance? Do you worry about falling?”</p> <p>If there is a positive answer to either question a referral to a strength and balance programme should be considered.</p>		

<b>Variable #</b>	4.06	<b>Variable</b>	Pre-fracture Strength
<b>Variable Name</b>	pfstrength	<b>Format</b>	Numeric
<b>Definition</b>	Was the patient able to stand up from a chair without using their hands prior to the index fracture?		
<b>Justification</b>	To assess the risk of falls and consequently the risk of further fragility fractures.		
<b>Coding Source</b>	<a href="https://www.hqsc.govt.nz/our-programmes/reducing-harm-from-falls/publications-and-resources/publication/1458/">https://www.hqsc.govt.nz/our-programmes/reducing-harm-from-falls/publications-and-resources/publication/1458/</a>		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Yes</li> <li>2. No</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	<p>Please record the answer to the question “Could you get out of a chair without using your hands before your fracture?”</p> <p>If unable to do this, a referral to a strength and balance programme should be considered.</p>		

<b>Variable #</b>	4.07	<b>Variable</b>	Strength and Balance Referrals
<b>Variable Name</b>	sbref	<b>Format</b>	Numeric
<b>Definition</b>	Was a referral made to a strength and balance training programme?		
<b>Justification</b>	To document whether the patient has been referred to a strength and balance training programme.		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Already attending a recognised group strength and balance programme</li> <li>2. Already engaged in a self-directed exercise programme</li> <li>3. Referred to a community group strength and balance programme.</li> <li>4. Referred to an in-home strength and balance programme.</li> <li>5. Referred to the “Training for Independence” programme.</li> <li>6. No referral made to / not appropriate for a strength and balance training programme.</li> <li>7. Patient declined.</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	<p>In New Zealand, referral pathways are variable depending on local programme availability (e.g., in home strength and balance programme).</p> <p>The FLS should record “ Referred to a community strength and balance programme” when:</p> <ul style="list-style-type: none"> <li>● The referrers have the sole option of referring to a community programme (no in-home programme available)</li> <li>● The referrer is required to refer to a community programme which itself assesses suitability for an in-home programme.</li> <li>● Referred to the “Training for Independence” programme (this is an ACC funded programme in New Zealand only).</li> </ul> <p>In New Zealand, community group strength and balance programmes are provided by an accredited provider.</p> <p>In Australia, options 1 and 3 refer to any ongoing exercise programme, supervised by a trained provider (volunteer, fitness leader, health, or exercise professional).</p> <p>For options 1, 2, 6, 7 and 9, no date is required for variable 4.08 Strength and Balance Referral Date.</p>		

<b>Variable #</b>	4.08	<b>Variable</b>	Strength and Balance Referral Date
<b>Variable Name</b>	sbrefdate	<b>Format</b>	date
<b>Definition</b>	What was the date a referral was made to a strength and balance training programme?		
<b>Justification</b>	To document the date that the patient was referred to a strength and balance training programme.		
<b>Coding Source</b>			
<b>Coding Frame</b>	dd/mm/yyyy 00/00/0000 = not done		
<b>Comments</b>	If the patient has been an inpatient, this would be the discharge date.		

<b>Variable #</b>	4.09	<b>Variable</b>	Information about Nymbi Provided
<b>Variable Name</b>	Nymbi	<b>Format</b>	Numeric
<b>Definition</b>	Was information about the Nymbi smart phone application provided to the patient?		
<b>Justification</b>	To document whether information about the Nymbi smart phone application was provided to the patient.		
<b>Coding Source</b>			
<b>Coding Frame</b>	1. Yes. 2. No.		
<b>Comments</b>	<p><b>New Zealand ONLY</b></p> <p>This question will only be answered if there is no referral to Strength and Balance classes or the patient declined referral to Strength and Balance classes.</p>		

<b>Variable #</b>	4.10	<b>Variable</b>	Referral for Specialist Falls Intervention
<b>Variable Name</b>	fallref	<b>Format</b>	Numeric / Multichoice
<b>Definition</b>	Was a referral made to another service (other than a strength and balance programme) for a falls related assessment or action plan		
<b>Justification</b>	To document whether the patient has been referred to another service (other than a strength and balance programme) for a falls related assessment or action plan.		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. No referral made.</li> <li>2. Physiotherapy</li> <li>3. Geriatric Medicine</li> <li>4. Community Occupational Therapist for an in-home safety review</li> <li>5. Falls Clinic / Service</li> <li>6. General Practitioner</li> <li>7. Pharmacist review</li> <li>8. Dietician</li> <li>9.</li> <li>10. General Medicine/Surgery</li> <li>11. Orthopaedics</li> <li>12.</li> <li>13.</li> <li>14. Other</li> <li>15. Rehabilitation in short-term Residential Care</li> <li>16. ED / Out of Hours services</li> <li>99.</li> </ol>		
<b>Comments</b>	See separate document regarding falls risk assessment and referrals.		

## 5. Investigation - DXA

<b>Variable #</b>	5.01	<b>Variable</b>	DXA Ordered or Not
<b>Variable Name</b>	dxaordnot	<b>Format</b>	Numeric
<b>Definition</b>	Was a DXA scan ordered and if not, what is the reason?		
<b>Justification</b>	Ability to monitor DXA scanning frequency and patient management against Clinical Care Standards.		
<b>Coding Source</b>	Adapted from the UK FLS-DB Proforma V2.00		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Ordered</li> <li>2. Declined</li> <li>3. Done in last 24 months and not being repeated at this time.</li> <li>4. Not appropriate</li> <li>5. Not available</li> <li>6. Ordered – did not attend</li> </ol>		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p><b>Ordered</b> means ordered to be done, this includes where someone else has ordered a DXA.</p> <p><b>Not appropriate</b> –includes the following reasons: DXA scan not indicated; DXA scan contraindicated.</p> <p><b>Not available</b> – i.e., DXA machine is not available.</p> <p>If DXA done in last 24 months, you have the option to include the results here including the date</p>		

<b>Variable #</b>	5.02	<b>Variable</b>	Date DXA Ordered
<b>Variable Name</b>	dxaorddate	<b>Format</b>	Date
<b>Definition</b>	What date was a DXA scan ordered?		
<b>Justification</b>	Ability to monitor DXA scanning frequency and availability.		
<b>Coding Frame</b>	dd/mm/yyyy 00/00/0000 not ordered.		

<b>Variable #</b>	5.03	<b>Variable</b>	DXA Date
<b>Variable Name</b>	dxadate	<b>Format</b>	Date
<b>Definition</b>	What date was a DXA scan performed?		
<b>Justification</b>	Ability to monitor DXA scanning frequency and patient management against Clinical Care Standards.		
<b>Coding Frame</b>	dd/mm/yyyy 00/00/0000 not ordered or did not attend		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>New Zealand Clinical Care Standards require the DXA to be completed within 12 weeks of the index fracture if DXA is recommended.</p>		

<b>Variable #</b>	5.04	<b>Variable</b>	DXA Spine T-score
<b>Variable Name</b>	dxaspine	<b>Format</b>	Numeric
<b>Definition</b>	What was the lowest DXA T-score in the L1-L4 region or the L2-L4 region?		
<b>Justification</b>	Ability to monitor DXA results and assess future fragility fracture risk.		
<b>Coding Frame</b>	.:___ 0.00 = Code for significant artefact / technical difficulty causing unreportable result		
<b>Comments</b>	Error controls of +6 to -6.		

<b>Variable #</b>	5.05	<b>Variable</b>	DXA Hip T-score
<b>Variable Name</b>	dxahip	<b>Format</b>	Numeric
<b>Definition</b>	What was the lowest DXA hip T-score?		
<b>Justification</b>	Ability to monitor DXA results and assess future fragility fracture risk.		
<b>Coding Frame</b>	.:___		
<b>Status</b>	Optional		
<b>Comments</b>	This is the T-score for either the total hip or the femoral neck. Error controls of +6 to -6.		



<b>Variable #</b>	5.06	<b>Variable</b>	DXA wrist T-score
<b>Variable Name</b>	dxawrist	<b>Format</b>	Numeric
<b>Definition</b>	What was the DXA T-score at the distal one third radius of the non-dominant forearm.		
<b>Justification</b>	Ability to monitor DXA results and assess future fragility fracture risk.		
<b>Coding Frame</b>	_.__		
<b>Comments</b>	<p>Error controls of +6 to -6.</p> <p>Baim S, Binkley N, Bilezikian JP, et al. Official position of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD position development conference. J Clin Densitom 2008; 11:75–91</p>		

## 7. Intervention

<b>Variable #</b>	6.01	<b>Variable</b>	Osteoporosis Specific Treatment Recommendation
<b>Variable Name</b>	treatrec	<b>Format</b>	Numeric
<b>Definition</b>	Was osteoporosis specific treatment recommended?		
<b>Justification</b>	Ability to measure service performance against Clinical Care Standards		
<b>Coding Source</b>	Adapted from UK FLS-DB V2.00		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Not clinically indicated.</li> <li>2. Recommended but declined.</li> <li>3. Referred to specialist.</li> <li>4. Continue current treatment.</li> <li>5. Continue current planned drug holiday.</li> <li>6. Bisphosphonate therapy (prescriber's choice)</li> <li>7. Alendronate</li> <li>8. Risedronate</li> <li>9. Zoledronate</li> <li>10. Denosumab</li> <li>11. Teriparatide</li> <li>12. Testosterone</li> <li>13. Systemic Oestrogens</li> <li>14. Systemic Oestrogen &amp; Progesterone</li> <li>15. Romosozumab</li> <li>16. Raloxifene</li> <li>99. Not known</li> </ol>		

<b>Variable #</b>	6.02	<b>Variable</b>	Reason Treatment Not Recommended
<b>Variable Name</b>	notrecreason	<b>Format</b>	Numeric
<b>Definition</b>	What is the reason that osteoporosis specific treatment is not recommended?		
<b>Justification</b>	To understand the reasons that lead to treatment not being recommended.		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. All assessments indicate treatment not required at present.</li> <li>2. Poor renal function</li> <li>3. Poor swallowing, severe GORD, Barrett’s oesophagus, achalasia</li> <li>4. Advanced frailty, life expectancy of less than a year</li> <li>5. Long term bisphosphonate treatment, so no further fracture risk benefit.</li> <li>6. Treatment indicated, but no funded alternatives available within Pharmac (NZ) or PBS (Aust) criteria.</li> <li>7. Atypical femur fracture</li> <li>8. History of Osteonecrosis of the Jaw or significant active dental disease or planned dental treatment.</li> <li>9. No obvious reason</li> <li>10. Did not attend DXA and no further FLS engagement</li> </ol>		
<b>Comments</b>	Note: long term bisphosphonate treatment means the patient has received many years of bisphosphonates (e.g., more than 5 years) and continuing bisphosphonate therapy will not reduce fracture risk further.		

<b>Variable #</b>	6.03	<b>Variable</b>	Date of Osteoporosis Treatment Recommendation
<b>Variable Name</b>	treatreccdate	<b>Format</b>	date
<b>Definition</b>	The date that a recommendation regarding osteoporosis specific treatment was made by the FLS.		
<b>Justification</b>	To measure the time for FLS to make a recommendation for osteoporosis specific treatment from the date of the index fracture(s) in accordance with the Clinical Standards for FLS in New Zealand.		
<b>Coding Source</b>			
<b>Coding Frame</b>	dd/mm/yyyy 99/99/9999 not done.		
<b>Status</b>	<b>Required for Clinical Standards for FLS in New Zealand</b>		
<b>Comments</b>			

<b>Variable #</b>	6.04	<b>Variable</b>	Vitamin D (ARCF)
<b>Variable Name</b>	vitdarc	<b>Format</b>	Numeric
<b>Definition</b>	If the person is living in an aged residential care facility, are they taking Vitamin D?		
<b>Justification</b>	To document whether people living in an aged residential care facility, are taking Vitamin D? This is recommended in RACGP Guideline for osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age, 2 <sup>nd</sup> edition, 2017.		
<b>Coding Source</b>			
<b>Coding Frame</b>	1 Yes 2 No 9 Not known		
<b>Comments</b>			

<b>Variable #</b>	6.05	<b>Variable</b>	Long Term Plan
<b>Variable Name</b>	ltplan	<b>Format</b>	Numeric
<b>Definition</b>	Was there a long-term care plan written for the patient?		
<b>Justification</b>	To know if a long-term care plan was developed		
<b>Coding Source</b>			
<b>Coding Frame</b>	1 Yes 2 No 9 Not known		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>The FLS develops a long-term care plan with patients and their general practitioner to reduce the risk of falls and fracture. Patients should receive the care plan which has been agreed between the FLS and general practitioner. This is required to meet the NZ Clinical Care Standards</p>		

<b>Variable #</b>	6.06	<b>Variable</b>	Long Term Plan Date
<b>Variable Name</b>	ltplandate	<b>Format</b>	date
<b>Definition</b>	The date that the long-term plan for fracture prevention management was made		
<b>Justification</b>	Ability to measure whether the long-term plan is developed in time to meet the Clinical Care Standards		
<b>Coding Source</b>			
<b>Coding Frame</b>	dd/mm/yyyy Code for not done		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>To meet the NZ Clinical Care Standards a long-term plan should be developed within 12 weeks of the index fracture.</p>		

<b>Variable #</b>	6.07	<b>Variable</b>	Information Package
<b>Variable Name</b>	infopack	<b>Format</b>	Multiple choice – numeric
<b>Definition</b>	Was a bone health information package provided?		
<b>Justification</b>	Ability to know if patients receive appropriate information about prevention of fragility fractures		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Yes – Standard package.</li> <li>2. Yes – Know Your Bones</li> <li>3. No</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>Provision of information refers to whether patients and family or carers are given written information in their own language on bone health, lifestyle measures (including exercise, alcohol, and smoking), nutrition (including calcium and vitamin D intake), sun exposure and the relationship between osteoporosis and fracture risk.</p> <p>Yes, to Know Your Bones if patient was given information to access the Know Your Bones website.</p> <p>This measure is part of the Clinical Care Standards for FLS.</p>		

<b>Variable #</b>	6.08	<b>Variable</b>	Standard Information Package Date
<b>Variable Name</b>	stdinfodate	<b>Format</b>	date
<b>Definition</b>	The date that the standard information package was provided.		
<b>Justification</b>	Ability to measure whether the standard information package was provided within 12 weeks as in the Clinical Care Standards for FLS in New Zealand.		
<b>Coding Source</b>			
<b>Coding Frame</b>	dd/mm/yyyy Code for not done 99/99/9999		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>To meet the NZ Clinical Care Standards an information package should be provided within 12 weeks of index fracture date.</p>		

## 7. Follow up at 16 Weeks

Note: Follow up is for patients for whom the FLS has recommended bone therapy.

<b>Variable #</b>	7.01	<b>Variable</b>	Follow Up At 16 Weeks
<b>Variable Name</b>	fup16	<b>Format</b>	Numeric
<b>Definition</b>	Was the patient followed up at 16 weeks after the index fracture		
<b>Justification</b>	To measure performance against Clinical Care Standard		
<b>Coding Source</b>	Adapted from UK FLS-DB V2.00		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Yes</li> <li>2. No</li> <li>3. Uncontactable</li> <li>4. Declined</li> <li>5. Patient died</li> </ol>		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>This section is only for patients who are recommended bone therapy because of the FLS intervention or for patients who are still awaiting a DXA scan for a definitive recommendation to be made.</p> <p>Where reasonably possible follow up should include contact with the patient via telephone.</p> <p>Follow up should be 16 weeks post index fracture (not 16 weeks post assessment).</p> <p>Late follow up – If follow up has been completed, but took place after 16 weeks, please answer ‘yes’. Example: Follow up may be delayed because awaiting DXA result before making treatment recommendation.</p> <p>‘No’ should only be selected if no follow up is planned.</p>		



<b>Variable #</b>	7.02	<b>Variable</b>	16 Week Follow Up Date
<b>Variable Name</b>	fup16date	<b>Format</b>	date
<b>Definition</b>	The date that the “16 week follow up” happened		
<b>Justification</b>	To measure performance against Clinical Care Standard		
<b>Coding Source</b>	Adapted from UK FLS-DB V2.00		
<b>Coding Frame</b>	dd/mm/yyyy		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>This section is only for patients who are recommended bone therapy because of the FLS intervention or for patients who are still awaiting a DXA scan for a definitive recommendation to be made.</p>		

<b>Variable #</b>	7.03	<b>Variable</b>	I6 Week Residence
<b>Variable Name</b>	ful6residence	<b>Format</b>	Numeric
<b>Definition</b>	What is the usual place of residence of the patient at the time of the I6 week follow up?		
<b>Justification</b>	This enables comparison of the type of accommodation of the person before suffering a fragility fracture with that at follow up assessments. This is an indicator of patient outcome.		
<b>Coding Source</b>	Adapted from the Australasian Rehabilitation Outcomes Centre Inpatient Dataset, Version 3.0; NSW SNAP Data Collection, Version 4.0		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Private residence (including unit in retirement village)</li> <li>2. Residential aged care facility</li> <li>3. Rehabilitation unit public</li> <li>4. Rehabilitation unit private</li> <li>5. Other hospital / ward / specialty</li> <li>6. Deceased</li> <li>7. Short term care in residential care facility (New Zealand only)</li> <li>97. Other</li> <li>99 Not known.</li> </ol>		
<b>Comments</b>	<ul style="list-style-type: none"> <li>● Record the patient's usual accommodation type the time of the I6 week follow up.</li> <li>● Residential aged care refers to a supported facility that provides accommodation and care for a person on a long-term basis. This may include multi-purpose services in Australia and private hospitals or rest homes in New Zealand.</li> <li>● If the patient lives with a relative or in a community group home or boarding house code 'private residence'.</li> <li>● If the patient is in respite care, record their usual place of residence when not in respite care.</li> </ul>		

<b>Variable #</b>	7.04	<b>Variable</b>	I6 Week Mobility
<b>Variable Name</b>	WalkI6fu	<b>Format</b>	Numeric
<b>Definition</b>	The patient's mobility status at the I6-week follow-up		
<b>Justification</b>	To document the patient's mobility at the time of the I6 week follow up.		
<b>Coding Source</b>	Adapted from ANZHFR Data Dictionary V13		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Usually walks without walking aids</li> <li>2. Usually walks with either a stick or crutch</li> <li>3. Usually walks with two aids or frame (with or without assistance of a person)</li> <li>4. Usually uses a wheelchair / bed bound</li> <li>8. Not relevant</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	If a person has different levels of mobility on different surfaces, then record the level of most assistance. For example, inside their residence a person usually walks without a walking aid but when outside the residence the person usually walks with a frame, then the level of mobility recorded is option 3.		

<b>Variable #</b>	7.05	<b>Variable</b>	Medication Commenced
<b>Variable Name</b>	Medstart	<b>Format</b>	Numeric
<b>Definition</b>	Has the patient commenced taking osteoporosis specific treatment?		
<b>Justification</b>	To document that the patient commenced prescribed osteoporosis specific treatment by the 16 week follow up.		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1.</li> <li>2.</li> <li>3. Yes – same as recommended</li> <li>4. Yes – not same as recommended</li> <li>5. No – not liaised with Primary Care at this time</li> <li>6. No – now declining treatment</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>The NZ Clinical Care Standard requires that the person begins an osteoporosis specific treatment within 16 weeks of the index fracture.</p>		

<b>Variable #</b>	7.06	<b>Variable</b>	I6 Week Medication
<b>Variable Name</b>	MedsI6fu	<b>Format</b>	Numeric
<b>Definition</b>	Which osteoporosis specific treatment has the patient commenced taking?		
<b>Justification</b>	To document the osteoporosis specific treatment the patient has commenced.		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Recommended but declined.</li> <li>2. Awaiting specialist opinion</li> <li>3. Clinical assessment not yet completed.</li> <li>4. Alendronate</li> <li>5. Risedronate</li> <li>6. Zoledronate</li> <li>7. Denosumab</li> <li>8. Teriparatide</li> <li>9. Testosterone</li> <li>10. Systemic Oestrogens</li> <li>11. Systemic Oestrogen &amp; Progesterone</li> <li>12. Romosozumab</li> <li>13. Raloxifene</li> <li>99. Not known</li> </ol>		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>The NZ Clinical Care Standard requires that the person begins an osteoporosis specific treatment within 16 weeks of the index fracture.</p> <p>Answer 3., if the treatment decision is delayed due to incomplete fracture risk assessment, e.g., awaiting DXA result.</p>		

<b>Variable #</b>	7.07	<b>Variable</b>	Strength and Balance Started
<b>Variable Name</b>	sbstartdate	<b>Format</b>	Numeric
<b>Definition</b>	Has the patient started participating in a strength and balance training programme?		
<b>Justification</b>	To document that the patient has started participating in the strength and balance training programme.		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1.</li> <li>2.</li> <li>3. Yes - same as referred</li> <li>4. Yes - not same as referred</li> <li>5. No - not started yet</li> <li>6. No - now declined</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>The NZ Clinical Care Standard requires that the person begins a strength and balance training programme within 16 weeks of the index fracture.</p> <p>If the answers to variable 4.07 Strength and Balance Referrals are options 1, 2, 6, 7, 9, this variable does not require an additional response.</p>		

## 8. Follow up at 52 Weeks (50-54 weeks)

<b>Variable #</b>	8.01	<b>Variable</b>	Follow Up At 52 Weeks
<b>Variable Name</b>	Fup52	<b>Format</b>	Numeric
<b>Definition</b>	Was the patient followed up at 52 weeks after the index fracture?		
<b>Justification</b>	To measure performance against Clinical Care Standard		
<b>Coding Source</b>	Adapted from UK FLS-DB V2.00		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Yes</li> <li>2. No</li> <li>3. Uncontactable</li> <li>4. Declined</li> <li>5. Patient died</li> </ol>		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <ul style="list-style-type: none"> <li>● This section is only for patients who are recommended osteoporosis specific treatment because of the FLS intervention.</li> <li>● Where reasonably possible follow up should include contact with the patient via telephone</li> <li>● Follow up should be at between 48 and 54 weeks after the index fracture (not 52 weeks post assessment).</li> <li>● Late follow up - If follow up has been completed, but took place after 54 weeks, please answer 'yes'.</li> <li>● 'No' should only be selected if no follow up is planned.</li> </ul>		

<b>Variable #</b>	8.02	<b>Variable</b>	52 Week Follow Up Date
<b>Variable Name</b>	Fup52date	<b>Format</b>	date
<b>Definition</b>	The date that the “52 week follow up” happened		
<b>Justification</b>	To measure performance against Clinical Care Standard		
<b>Coding Source</b>	Adapted from UK FLS-DB V2.00		
<b>Coding Frame</b>	dd/mm/yyyy 00/00/0000 = not followed up		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>This section is only for patients who are recommended osteoporosis specific treatment because of the FLS intervention.</p>		



<b>Variable #</b>	8.03	<b>Variable</b>	52 Week Residence
<b>Variable Name</b>	Fu52residence	<b>Format</b>	Numeric
<b>Definition</b>	What is the usual place of residence of the patient at the time of the 52 week follow up?		
<b>Justification</b>	This enables comparison of the type of accommodation of the person before suffering a fragility fracture with that at follow up assessments. This is an indicator of patient outcome.		
<b>Coding Source</b>	Adapted from the Australasian Rehabilitation Outcomes Centre Inpatient Dataset, Version 3.0; NSW SNAP Data Collection, Version 4.0		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Private residence (including unit in retirement village)</li> <li>2. Residential aged care facility</li> <li>3. Other</li> <li>4. Not done</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	<ul style="list-style-type: none"> <li>● Record the patient's usual accommodation type the time of the 16 week follow up.</li> <li>● Residential aged care refers to a supported facility that provides accommodation and care for a person on a long-term basis. This may include multi-purpose services in Australia and private hospitals or rest homes in New Zealand.</li> <li>● If the patient lives with a relative or in a community group home or boarding house code 'private residence'.</li> <li>● If the patient is in respite care, record their usual place of residence when not in respite care.</li> </ul>		

<b>Variable #</b>	8.04	<b>Variable</b>	52 Week Mobility
<b>Variable Name</b>	Walk52fu	<b>Format</b>	Numeric
<b>Definition</b>	The patient's mobility status at the 52-week follow-up		
<b>Justification</b>	To document the patient's mobility at the time of the 52 week follow up.		
<b>Coding Source</b>	Adapted from ANZHFR Data Dictionary V13		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Usually walks without walking aids.</li> <li>2. Usually walks with either a stick or crutch.</li> <li>3. Usually walks with two aids or frame (with or without assistance of a person)</li> <li>4. Usually uses a wheelchair / bed bound.</li> <li>5. Not done</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	<p>If a person has different levels of mobility on different surfaces, then record the level of most assistance. For example, inside their residence a person usually walks without a walking aid but when outside the residence the person usually walks with a frame, then the level of mobility recorded is option 3.</p>		

<b>Variable #</b>	8.05	<b>Variable</b>	52 Week Medication
<b>Variable Name</b>	Med52	<b>Format</b>	Numeric
<b>Definition</b>	Did the patient confirm adherence to osteoporosis specific treatment		
<b>Justification</b>	To document whether the patient was still taking osteoporosis specific treatment		
<b>Coding Source</b>	Adapted from UK FLS-DB V2.00		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>0. Never started taking osteoporosis specific treatment</li> <li>1. No longer taking osteoporosis specific treatment.</li> <li>2. Alendronate</li> <li>3. Risedronate</li> <li>4. Zoledronate</li> <li>5. Denosumab</li> <li>6. Teriparatide</li> <li>7. Testosterone</li> <li>8. Systemic Oestrogens</li> <li>9. Systemic Oestrogen &amp; Progesterone</li> <li>10. Romosozumab</li> <li>11. Raloxifene</li> </ol>		
<b>Comments</b>	<p><b>Required for Clinical Standards for FLS in New Zealand</b></p> <p>A patient is to be considered as ‘on/taking bone protection medication’ if:</p> <ul style="list-style-type: none"> <li>● For oral-osteoporosis agents, patient prescribed in the last 12 weeks.</li> <li>● For Zoledronate, administered in the last 24 months.</li> <li>● For Denosumab, administered the last 6 months.</li> <li>● For Teriparatide, administered in the last 7 days.</li> <li>● For Romosozumab, administered in the last month.</li> </ul> <p>Online review of prescriptions may indicate that the patient is taking osteoporosis medication regularly – this is satisfactory. If there is no evidence of this online – patient and / or GP interview will be required.</p> <p>In Australia information will be only from patient interview. In NZ information is from a combination of patient interview and electronic linkage</p>		

<b>Variable #</b>	8.06	<b>Variable</b>	Reason for No Medication at 52 Weeks
<b>Variable Name</b>	NoMed52	<b>Format</b>	Numeric
<b>Definition</b>	What was the reason for the patient not taking recommended osteoporosis specific treatment at 52 week follow up?		
<b>Justification</b>	To document the reason the patient was no longer taking osteoporosis specific treatment.		
<b>Coding Source</b>	Adapted from UK FLS-DB V2.00		
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. No longer appropriate (clinician)</li> <li>2. Informed decline (patient)</li> <li>3. Side effects</li> <li>4. Cost to patient</li> <li>5. Nil obvious</li> <li>6. Other</li> <li>7. Not asked</li> <li>8. No medication prescribed by Primary Care</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	<p>If the patient's GP or other healthcare professional stops the specific osteoporosis medication for whatever reason (including side effects), please select 'No longer appropriate (clinician).'</p> <p>If the patient stops the medication by the time of the follow up, please select 'Informed decline (patient)'</p>		

<b>Variable #</b>	8.07	<b>Variable</b>	Further Falls
<b>Variable Name</b>	furtherfall	<b>Format</b>	Numeric
<b>Definition</b>	The number of further falls the patient has suffered since the index fracture		
<b>Justification</b>	To document the number of further falls since the index fragility fracture suffered by the patient as a measure of patient outcome.		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. None</li> <li>2. One</li> <li>3. Two</li> <li>4. Three or more</li> <li>5. Not asked</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	This is a measure of patient outcome. This is the answer to the question “since the index fracture, have you had any further falls in the last 12 months” or similar.		

<b>Variable #</b>	8.08	<b>Variable</b>	Strength and Balance
<b>Variable Name</b>	SBpartic	<b>Format</b>	Numeric
<b>Definition</b>	Is the patient still participating in a strength and balance programme?		
<b>Justification</b>	To document whether the patient is still participating in strength and balance training.		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1.</li> <li>2.</li> <li>3. Yes - same as referred</li> <li>4. Yes - not same as referred</li> <li>5. No - not started yet</li> <li>6. No - now declined</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	<p>In the context of this question, a strength and balance programme means that the patient is still carrying out some form of regular activity that aims to improve / maintain their strength and balance. This could be the continuation of an in-home programme that has previously been set or regular attendance at an appropriate community programme. A self-directed programme of regular exercise is also satisfactory e.g., Nymbi in New Zealand.</p>		

<b>Variable #</b>	8.09	<b>Variable</b>	Further Fractures
<b>Variable Name</b>	furtherfract	<b>Format</b>	Numeric
<b>Definition</b>	Has the patient had a further fragility fracture since the index fracture 52 weeks ago?		
<b>Justification</b>	To document whether the patient has had a further fragility fracture since the index fracture 52 weeks ago.		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Yes</li> <li>2. No</li> <li>3. Not asked</li> <li>9. Not known</li> </ol>		
<b>Comments</b>	This is to ensure that a further fragility fracture has not occurred since the index fracture, and not been identified by the usual identification procedures.		

## 9. Additional Outcomes

<b>Variable #</b>	9.01	<b>Variable</b>	Date of Death
<b>Variable Name</b>	datedeath	<b>Format</b>	date
<b>Definition</b>	What is the date of death of the patient?		
<b>Justification</b>	To enable measurement of mortality related to fragility fractures		
<b>Coding Source</b>			
<b>Coding Frame</b>	DD/MM /YYYY		
<b>Comments</b>	This will be completed by data linkage with Ministry of Health Mortality Collection		



## List of Data Variables for ANZFFR Facility Level Audit

<b>Variable #</b>	6.01	<b>Variable</b>	FLS Team Meeting Frequency
<b>Variable Name</b>	MeetFreqLCL	<b>Format</b>	Numeric
<b>Definition</b>	Frequency of meetings between FLS Co-ordinators and local Clinical Lead to discuss FLS patients and process		
<b>Justification</b>	To ensure suitable oversight of team clinical decision-making by a vocationally registered senior doctor		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Weekly</li> <li>2. Fortnightly</li> <li>3. Monthly</li> <li>4. Quarterly</li> <li>5. Less frequent or only as required</li> </ol>		
<b>Comments</b>	Planned regular meetings (including by Zoom or Teams) where Registry patients are presented for collective decisions on further action. Add other timetabled whole-team meetings discussing service development. Do not include one-to-one conversations about individual patients. Where your result lies between two options, round <b>up</b> to the higher/longer option.		

<b>Variable #</b>	6.02	<b>Variable</b>	FLS External Liaison
<b>Variable Name</b>	MeetFreqExt	<b>Format</b>	Numeric
<b>Definition</b>	Frequency of meetings with other service providers with responsibility for provision of services engaging and/or overlapping with FLS activity		
<b>Justification</b>	To monitor integration of FLS with the broader health and social care network in the locality		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Weekly</li> <li>2. One or two per month</li> <li>3. One or two per quarter</li> <li>4. One to three a year</li> <li>5. None in last year</li> </ol>		
<b>Comments</b>	Examples include hospital or community Falls Prevention Working Groups, community-based falls prevention teams, Geriatric and Ortho-geriatric service team meetings. At least two of your team including the Clinical Lead must be notified of meetings and at least one of you must have attended.		

<b>Variable #</b>	6.03	<b>Variable</b>	Annual Report Value 1
<b>Variable Name</b>	AnnReportVal1	<b>Format</b>	Numeric
<b>Definition</b>	Which component of the FFR Annual Report did your team think was of most value for your professional development? (Select your FIRST choice)		
<b>Justification</b>	To understand how to improve the utility of the FFR Annual Report as a tool for internal service development.		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Graphs with site comparison</li> <li>2. Graphs National Line percentage</li> <li>3. Stakeholder information</li> <li>4. Patient &amp; Team Stories</li> <li>5. Other</li> </ol>		
<b>Comments</b>			

<b>Variable #</b>	6.04	<b>Variable</b>	Annual Report Value 2
<b>Variable Name</b>	AnnReportVal2	<b>Format</b>	Numeric
<b>Definition</b>	Which component of the FFR Annual Report did your team think was of most value for your professional development? (Select your SECOND choice)		
<b>Justification</b>	To understand how to improve the utility of the FFR Annual Report as a tool for internal service development.		
<b>Coding Source</b>			
<b>Coding Frame</b>	<ol style="list-style-type: none"> <li>1. Graphs with site comparison</li> <li>2. Graphs National Line percentage</li> <li>3. Stakeholder information</li> <li>4. Patient &amp; Team Stories</li> <li>5. Other</li> </ol>		
<b>Comments</b>			

<b>Variable #</b>	6.05	<b>Variable</b>	Annual Report Value 3
<b>Variable Name</b>	AnnReportVal3	<b>Format</b>	Text
<b>Definition</b>	If you answered “Other” to either of the above two questions or if you wish to give further feedback on the Annual Report, please enter it here.		
<b>Justification</b>	To understand how to improve the utility of the FFR Annual Report as a tool for internal service development.		
<b>Coding Source</b>			
<b>Coding Frame</b>	Text		
<b>Comments</b>			

<b>Variable #</b>	6.06	<b>Variable</b>	Database improvement
<b>Variable Name</b>	DBimprov	<b>Format</b>	Text
<b>Definition</b>	Describe any way in which we could improve the usefulness of the FFR Database for your team in their day-to-day work.		
<b>Justification</b>	To feed into the Registry database development workstream		
<b>Coding Source</b>			
<b>Coding Frame</b>	Text		
<b>Comments</b>			

<b>Variable #</b>	6.07	<b>Variable</b>	Continuing Professional Development
<b>Variable Name</b>	cpd	<b>Format</b>	Text
<b>Definition</b>	Description of continuing professional development undertaken by ALL of the FLS team in the last year.		
<b>Justification</b>	To document evidence that members of each FLS undertake continuing professional development activity every year		
<b>Coding Source</b>			
<b>Coding Frame</b>	Text		
<b>Comments</b>	List each team member (including Clinical Lead) separately with a brief description of any relevant courses/study they have undertaken, how long they spent on it and what they gained from it. Attendance at Fracture Fest is eligible.		